About this course

Learning Objectives

• Identify 2 medications approved for treatment of eating disorders.
• Recognize at least 2 of the most common co-occurring mental health diagnoses in clients with eating disorders
• Describe the importance of a comprehensive mental and physical health evaluation for clients presenting with eating disorders
• Recognize common medical complications/concerns stemming from eating disorders symptoms/behaviors and/or the treatment process.

Learning Levels

• Intermediate

Target Audience

Course Instructor(s)

• 

  Brad E.R. Smith, MD, DFAPA

  Chief Medical Officer

  Dr. Brad Smith, MD, DFAPA (he/him) is the Chief Medical Officer for Accanto Health, overseeing the clinical direction of The Emily Program and Gather Behavioral Health. With 25 years of experience in psychiatry and medical leadership, he is dedicated to advancing high-quality, patient-centered care for individuals with eating disorders.

  Board-certified in adult and forensic psychiatry, Dr. Smith has spent his career developing innovative, evidence-based treatment programs. Before joining Accanto Health, he directed clinical services at all levels of care within Eating Disorder Recovery Services at Rogers Behavioral Health. He is recognized for his leadership in improving clinical outcomes and expanding access to care for those in need.

  Dr. Smith earned his medical degree from the University of Wisconsin, where he also completed his psychiatry residency, serving as chief resident in his final year. He completed a fellowship in forensic psychiatry at the Medical College of Wisconsin and is a Distinguished Fellow of the American Psychiatric Association, an honor that highlights his substantial contributions to the field.

  In addition to his clinical leadership, Dr. Smith is passionate about education and has served as a voluntary assistant clinical professor in the Department of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin. He has lectured nationally on a wide range of topics related to eating disorders and mental health, including peer-selected presentations for the National Eating Disorders Association and the Multi-Service Eating Disorders Association annual meetings.

• Mike Donndelinger, MD

  Dr. Michael Donndelinger is Psychiatrist in both Adult Psychiatry and Child and Adolescent Psychiatry. Dr. Donndelinger completed his undergraduate degree in genetics and cell biology and graduated with honors from the University of Minnesota. He went on to medical school, residency, and his Child and Adolescent Fellowship also at The University of Minnesota. He has been with The Emily Program since 2008 and is also the medical director at Minnesotan Mental Health Clinics.

Disclosure

References

• Kan C, Eid L, Treasure J, Himmerich H. A Meta-Analysis of Dropout and Metabolic Effects of Antipsychotics in Anorexia Nervosa. Front Psychiatry. 2020 Mar 17;11:208. doi: 10.3389/fpsyt.2020.00208. PMID: 32256415; PMCID: PMC7090227.
• Aigner M, Treasure J, Kaye W, Kasper S; WFSBP Task Force on Eating Disorders: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry 2011; 12:400–443
• Attia, E., Steinglass, J. E., Walsh, B. T., Wang, Y., Wu, P., Schreyer, C., Wildes, J., Yilmaz, Z., Guarda, A. S., Kaplan, A. S., & Marcus, M. D. (2019). Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial. The American journal of psychiatry, 176(6), 449–456. https://doi.org/10.1176/appi.ajp.2018.18101125
• Blanchet, C., Guillaume, S., Bat-Pitault, F., Carles, M. E., Clarke, J., Dodin, V., Duriez, P., Gerardin, P., Hanachi-Guidoum, M., Iceta, S., Leger, J., Segrestin, B., Stheneur, C., & Godart, N. (2019). Medication in AN: A Multidisciplinary Overview of Meta-Analyses and Systematic Reviews. Journal of clinical medicine, 8(2), 278. https://doi.org/10.3390/jcm8020278
• McElroy S. L. (2017). Pharmacologic Treatments for Binge-Eating Disorder. The Journal of clinical psychiatry, 78 Suppl 1, 14–19. https://doi.org/10.4088/JCP.sh16003su1c.03
• Brewerton, T. D., & D'Agostino, M. (2017). Adjunctive Use of Olanzapine in the Treatment of Avoidant Restrictive Food Intake Disorder in Children and Adolescents in an Eating Disorders Program. Journal of child and adolescent psychopharmacology, 27(10), 920–922. https://doi.org/10.1089/cap.2017.0133
• Gray, E., Chen, T., Menzel, J., Schwartz, T., & Kaye, W. H. (2018). Mirtazapine and Weight Gain in Avoidant and Restrictive Food Intake Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 57(4), 288–289. https://doi.org/10.1016/j.jaac.2018.01.011
• Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020). Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers in psychiatry, 11, 595584. https://doi.org/10.3389/fpsyt.2020.595584
• McIntyre, R. S., Cha, D. S., Kim, R. D., & Mansur, R. B. (2013). A review of FDA-approved treatment options in bipolar depression. CNS spectrums, 18 Suppl 1, 4–21. https://doi.org/10.1017/S1092852913000746
• Marvanova, M., & Gramith, K. (2018). Role of antidepressants in the treatment of adults with anorexia nervosa. The mental health clinician, 8(3), 127–137. https://doi.org/10.9740/mhc.2018.05.127
• Blanchet, C., Guillaume, S., Bat-Pitault, F., Carles, M. E., Clarke, J., Dodin, V., Duriez, P., Gerardin, P., Hanachi-Guidoum, M., Iceta, S., Leger, J., Segrestin, B., Stheneur, C., & Godart, N. (2019). Medication in AN: A Multidisciplinary Overview of Meta-Analyses and Systematic Reviews. Journal of clinical medicine, 8(2), 278. https://doi.org/10.3390/jcm8020278